Selected Publications
Karajannis MA, Onar-Thomas A, Lin T, Baxter PA, Boué DR, Cole BL, Fuller C, Haque S, Jabado N, Lucas JT Jr, MacDonald SM, Matsushima C, Patel N, Pierson CR, Souweidane MM, Thomas DL, Walsh MF, Zaky W, Leary SES, Gajjar A, Fouladi M, Cohen KJ. Phase 2 Trial of Veliparib, Local Irradiation and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma: A Children's Oncology Group Study. Neuro Oncol 2024 Nov 19:noae247. doi: 10.1093/neuonc/noae247. Epub ahead of print. PMID: 39560182.
Ramsey SD, Onar-Thomas A, Wheeler SB. Real-world database studies in oncology: A call for standards. J Clin Oncol 42:977-980, 2024.
Margol AS, Molinaro AM, Onar-Thomas A, Resnick A, Hanson D, Kieran M, Mishra-Kalyani P, Rivera D, Barone A, Arons D, Meehan C, Prados M. Use of external control cohorts in pediatric brain tumor clinical trials. J Clin Oncol 42:1340-1343, 2024.
Chiang J, Bagchi A, Li X, Dhanda SK, Huang J, Pinto SN, Sioson E, Dalton J, Tatevossian RG, Jia S, Partap S, Fisher PG, Bowers DC, Hassall TEG, Lu C, Zaldivar-Peraza A, Wright KD, Broniscer A, Qaddoumi I, Upadhyaya SA, Vinitsky A, Sabin ND, Orr BA, Klimo P Jr, Boop FA, Ashford JM, Conklin HM, Onar-Thomas A, Zhou X, Ellison DW, Gajjar A, Robinson GW. High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse: Results from the SJYC07 trial and institutional experience. Neuro Oncol 26:178-190, 2024.
Wang JX, Li Y, Reddick WE, Conklin HM, Glass JO, Onar-Thomas A, Gajjar A, Cheng C, Lu Z. A High-dimensional Mediation Model for a Neuroimaging Mediator: Integrating Clinical, Neuroimaging, and Neurocognitive Data to Mitigate Late Effects in Pediatric Cancer. Biometrics 79:2430-2443, 2023.
Onar-Thomas A. Adaptive Randomization: Full of Promise with a Helping of Caution. J Clin Oncol 41:5497-5500, 2023.
Monje M, Cooney T, Glod J, Huang J, Peer CJ, Faury D, Baxter P, Kramer K, Lenzen A, Robison NJ, Kilburn L, Vinitsky A, Figg WD, Jabado N, Fouladi M, Fangusaro J, Onar-Thomas A, Dunkel IJ, Warren KE, A Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium (PBTC-047). Neuro-Oncology 25:2262-2272, 2023.
Smith KS, Bihannic L, Gudenas BL, Haldipur P, Tao R, Gao Q, Li Y, Aldinger KA, Iskusnykh IY, Chizhikov VV, Scoggins M, Zhang S, Edwards A, Deng M, Glass IA, Overman LM, Millman J, Sjoboen AH, Hadley J, Golser J, Mankad K, Sheppard H, Onar-Thomas A, Gajjar A, Robinson GW, Hovestadt V, Orr BA, Patay Z, Millen KJ, Northcott PA. Unified rhombic lip origins of group 3 and group 4 medulloblastoma. Nature 2022 Sep;609(7929):1012-1020. doi: 10.1038/s41586-022-05208-9. Epub 2022 Sep 21. PMID: 36131015; PMCID: PMC9748853.
Liu A, Smith K, Kumar R, Paul L, Lin T, Maass KK, Pajtler KW, Chintagumpala M, Su JM, Bouffet E, Fisher MJ, Gururangan S, Cohn R, Hassall T, Hansford JR, Klimo P, Boop FA, Stewart CF, Harreld JH; Merchant TE, Tatevossian RG, Neale G, Lear M, Klco JM, Orr BA, Ellison DW, Gilbertson RJ, Onar-Thomas A, Gajjar A, Robinson GW, Northcott PA. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell Nov 8;39(11):1519-1530.e4, 2021.
Gajjar A, Robinson GW, Smith KS, Lin T, Merchant TE, Chintagumpala M, Mahajan A, Su J, Bouffet E, Bartels U, Schechter T, Hassall T, Robertson T, Nicholls W, Gururangan S, Schroeder K, Sullivan M, Wheeler G, Hansford JR, Kellie SJ, McCowage G, Cohn R, Fisher MJ, Krasin MJ, Stewart CF, Broniscer A, Buchhalter I, Tatevossian RG, Orr BA, Neale G, Klimo P, Boop F, Srinivasan A, Pfister SM, Gilbertson RJ, Onar-Thomas A, Ellison DW, Northcott PA. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol Mar 1;39(7):822-835, 2021.
Kumar R, Smith KS, Robinson GW, Deng M, Orr BA, Anthony PYL, Lin T, Billups C, Terhune C, Dhall G, Kleese L, Bowers D, Chintagumpala M, Leary S, Nazarian J, McLendon R, Packer R, Dunham C, Hukin J, Fouladi M, Faria C, Pimentel J, Walter A, Jabado N, Fontebasso A, Cho J, Perreault S, Croul S, Zapotocky Z, Sumerauer D, Hawkins C, Bouffet E, Tabori U, Taylor M, Pfister SM, Onar-Thomas A, Korshunov A, Gajjar A, Jones DTW, Ramaswamy V, Northcott PA. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology 39(7):807-821, 2021.
Fangusaro J, Wu S, MacDonald S, Murphy E, Shaw D, Bartels U, Khatua S, Williams-Hughes C, Souweidane M, Lu SM, Morris D, Panigrahy A, Onar-Thomas A, Fouladi M, Gajjar A, Dhall G. Outcomes of a Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Non-Germinomatous Germ Cell Tumors: A Children's Oncology Group Study, ACNS1123. J Clin Oncol Dec 1;37(34):3283-3290, 2019.
Renfro LA, Ji L, Piao J, Onar-Thomas A, Kairalla JA, Alonzo TA. Trial Design Challenges and Solutions for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group. JCO Precision Oncology in Special Series: Statistical Methods in Precision Oncology 3:1-13, 2019.
Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn L, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman S, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, , Patay Z, Tamrazi B, Jones JY, Haque S, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ*, Fouladi M*. Selumetinib in Children with BRAF-Aberrant or Neurofibromatosis type 1-Associated Recurrent, Refractory or Progressive Low-Grade Glioma: a Multi-Center Phase II Trial. Lancet Oncol Jul;20(7):1011-102, 2019.
Robinson GW, Rudneva VA, Buchhalter I, Billups C, Waszak S, Smith K, Bowers DC, Bendel A, Fisher A, Partap S, Crawford J, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A, Northcott PA. Risk-adapted therapy for young children with medulloblastoma (SJYC07): results and molecular analysis from a prospective, multicenter phase II trial. Lancet Oncology 19(6):768-784, 2018. PMID: 29778738, PMCID: PMC6078206.
Zhu L, Poppleton Finkelstein D, Shi L, Wang M, Terrada DL, Wang K, Utley S, Pounds S, Neale J, Ellison DW, Onar-Thomas A*, Gilbertson1 RJ*. Multi-organ mapping of cancer risk. Cell 166(5):1132-1146.e7, 2016. (* Co-corresponding author).
Last update: January 2025